January 15, 2011 -- Shanghai Pharma will acquire a 65% stake in China Health System, the third-largest drug distributor in Beijing, for $353 million; Sinopharm will purchase 80% of an Aurobindo Pharma antibiotic API subsidiary in China; PPD will offer biologic drug discovery services through its BioDuro subsidiary; United Laboratories will invest $150 million to gain a foothold in China’s insulin market; ShangPharma opened a new cGMP manufacturing facility in a Shanghai suburb; China’s Ministry of Health aims to cap each patient’s contribution to their own healthcare costs to 30%; and Zhang Jingli, one of four Deputy Directors of the SFDA, was officially fired from his post for corruption. More details….
